Parallel Advisors’s Aquestive Therapeutics AQST Stock Holding History

Parallel Advisors’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-100	Closed	-$202	–	3303
2023 Q4	$202	Buy	+100	New	+$177	﹤0.01%	3169

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MIM

Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Parallel Advisors's AQST Position: Q1 2024 in Review

Parallel Advisors sold out of Aquestive Therapeutics (AQST) in Q1 2024, closing a stake of 100 shares — an estimated $202 sold.

Parallel Advisors first reported a position in AQST in Q4 2023 and held it in 1 quarter. The position peaked at $202 in Q4 2023. 97 funds tracked by Wall St. Rank hold AQST as of Q1 2024.

Parallel Advisors reported no remaining Aquestive Therapeutics position as of Q1 2024 after selling out during the quarter.
Parallel Advisors sold 100 Aquestive Therapeutics shares in Q1 2024, an estimated $202.
Parallel Advisors first reported a position in Aquestive Therapeutics in Q4 2023 and held it in 1 quarter.
Parallel Advisors's Aquestive Therapeutics position peaked at $202 in Q4 2023.
97 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2024.

Based on Parallel Advisors's 13F filing for Q1 2024, filed 6 May 2024.